Predicting the risk of prostate cancer in asymptomatic men: a cohort study to develop and validate a novel algorithm
Open Access
- 9 December 2020
- journal article
- research article
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 71 (706) , e364-e371
Abstract
Background: Diagnosis of prostate cancer at an early stage can potentially identify tumours when intervention may improve treatment options and survival.Aim: To develop and validate an equation to predict absolute risk of prostate cancer in asymptomatic men with prostate specific antigen (PSA) tests in primary care.Design and setting: Cohort study using data from English general practices, held in the QResearch database.Method: Routine data were collected from 1098 QResearch English general practices linked to mortality, hospital, and cancer records for model development. Two separate sets of practices were used for validation. In total, there were 844 455 men aged 25–84 years with PSA tests recorded who were free of prostate cancer at baseline in the derivation cohort; the validation cohorts comprised 292 084 and 316 583 men. The primary outcome was incident prostate cancer. Cox proportional hazards models were used to derive 10-year risk equations. Measures of performance were determined in both validation cohorts.Results: There were 40 821 incident cases of prostate cancer in the derivation cohort. The risk equation included PSA level, age, deprivation, ethnicity, smoking status, serious mental illness, diabetes, BMI, and family history of prostate cancer. The risk equation explained 70.4% (95% CI = 69.2 to 71.6) of the variation in time to diagnosis of prostate cancer (R2) (D statistic 3.15, 95% CI = 3.06 to 3.25; Harrell’s C-index 0.917, 95% CI = 0.915 to 0.919). Two-step approach had higher sensitivity than a fixed PSA threshold at identifying prostate cancer cases (identifying 68.2% versus 43.9% of cases), high-grade cancers (49.2% versus 40.3%), and deaths (67.0% versus 31.5%).Conclusion: The risk equation provided valid measures of absolute risk and had higher sensitivity for incident prostate cancer, high-grade cancers, and prostate cancer mortality than a simple approach based on age and PSA threshold.Keywords
This publication has 44 references indexed in Scilit:
- Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-upJNCI: Journal of the National Cancer Institute, 2012
- Predicting the risk of Chronic Kidney Disease in Men and Women in England and Wales: prospective derivation and external validation of the QKidney®ScoresBMC Family Practice, 2010
- An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort studyBMJ, 2009
- Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScoreBMJ, 2009
- Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation studyHeart, 2007
- Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort studyBMJ, 2007
- Prostate cancer and schizophreniaUrology, 2006
- Using the outcome for imputation of missing predictor values was preferredJournal of Clinical Epidemiology, 2006
- Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention TrialJNCI: Journal of the National Cancer Institute, 2006
- A new measure of prognostic separation in survival dataStatistics in Medicine, 2004